Flow Neuroscience

Industry
Medical Devices & Equipment
Founded Year
2016
Headquarters
Malm, Sweden
Employee Count
49

Key People

Assessment

Team
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with backgrounds in technology and healthcare.

The leadership includes individuals with extensive experience in global technology companies and healthcare, providing a strong foundation for the company's strategic direction and product development.

Clinical Need
Aspect: Very Strong
Summary: Depression is a prevalent mental health disorder with significant unmet needs for effective treatments.

With millions affected globally and existing treatments often having limitations, innovative solutions like Flow's tDCS device offer promising alternatives to traditional therapies.

Competition
Aspect: Somewhat crowded
Summary: The mental health device market has several players, but Flow's unique approach differentiates it.

Competitors include companies offering pharmacological treatments and other neuromodulation devices; however, Flow's integrated approach may offer advantages in efficacy and user experience.

Technical Challenge
Aspect: Moderate
Summary: Developing and validating a medical device for at-home use presents moderate technical challenges.

The device must meet stringent regulatory standards and demonstrate consistent performance across diverse user populations, which requires robust engineering and clinical validation.

Patent
Aspect: Strong
Summary: Flow Neuroscience holds multiple patents related to its tDCS technology.

Patents covering the device's design and functionality help protect against market competition and support potential licensing opportunities.

Financing
Aspect: Well-funded
Summary: The company has secured significant funding from reputable investors.

With over $16 million raised, including a $9 million Series A round, Flow is positioned to advance its clinical programs and pursue regulatory approvals.

Regulatory
Aspect: 510k/PMA
Summary: Flow's device has received medical device certification in the EU and is pursuing FDA approval.

EU certification allows market entry in Europe, while ongoing efforts toward FDA approval aim to expand the product's availability to the U.S. market.

Opportunity Rollup

Odds of Success
3.6
Peak Market Share
4.6
Segment CAGR
4.9%
Market Segment
Neurology Devices
Market Sub Segment
Depression Treatment Devices
Year Post Launch Market Penetration (%)
1 0.23
2 0.69
3 1.61
4 3.22
5 4.60

Key Takeaway

Flow Neuroscience's innovative approach to depression treatment positions it well in a growing market, though it faces challenges in regulatory approval and market penetration.